A Forbion-funded startup bought the rights to Amgen's CETP inhibitor, and is giving the cholesterol drug another go
Forbion-funded startup NewAmsterdam Pharma has acquired the rights to obicetrapib: the CETP inhibitor that CEO Michael Davidson always thought would be the “crowning” of his career.
The announcement comes five years after Forbion sold Dezima Pharma and obicetrapib, its sole product, to Amgen for an up-front payment of $300 million. Amgen halted development in 2017, shortly after Eli Lilly, Pfizer, Roche and Merck walked away from their own CETP drugs. Former Pfizer R&D chief John LaMattina even suggested that Amgen might be better off cutting its losses just weeks after acquiring the drug.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters